MAM
InMobi Advertising enhances CMP for advanced privacy compliance
Mumbai: InMobi Advertising, a provider of content monetisation and marketing technologies, has launched the next generation of the InMobi consent management platform (InMobi CMP). This self-service solution helps publishers align with changing global privacy regulations. InMobi CMP is a robust privacy management platform for mobile publishers, enabling them to navigate the complex privacy landscape.
Privacy regulations such as the General Data Protection Regulation (GDPR) in Europe and the California Consumer Privacy Act (CCPA), along with standards like the Multi-State Privacy Agreement (MSPA), are continually evolving. InMobi CMP now helps more publishers foster user trust, enhance ad revenue, and ensure compliance by supporting the Global Privacy Platform (GPP) and offering expanded customisation for Unity apps.
Two key features of this update include:
1. Global privacy platform (GPP) support for apps and websites: InMobi CMP supports GPP for websites and apps (Android, iOS, and Unity). Implementing GPP ensures compliance with MSPA, covering regulations in California (CCPA), Colorado (CPA), Connecticut (CTDPA), Utah (UCPA), and Virginia (VCDPA).
2. New UI customisation for Unity apps: Publishers can now personalise their consent models for any app, including Unity apps. This customisation feature allows adjustments to color schemes and font styles on consent prompts, improving user experience and consent rates.
“Consumers are becoming increasingly aware of their data rights and InMobi Advertising has always been at the forefront of building solutions that help brands and publishers navigate the complex global privacy landscape,” said InMobi Advertising CEO Abhay Singhal. “For publishers, implementing robust consent management practices, like the InMobi CMP, demonstrates transparency and commitment to user privacy, building trust and improving engagement. By prioritising user experience and boosting consent rates, publishers can unlock increased advertiser demand for consented traffic.”
According to a recent survey by InMobi Advertising, over 87 per cent of mobile phone users believe apps should protect their privacy, yet only 42 per cent feel that they do. Closing this expectation gap is crucial, as 77 per cent of respondents stated that trust in an app influences their likelihood to make in-app purchases.
“BrainWave Games is committed to prioritising user privacy while navigating the challenges posed by ever-changing regulations,” said BrainWave Games CEO Mia Chen. “It’s not just about compliance but also about building user trust. Our consent management process focuses on user experience, ensuring it is easy to understand and use while seamlessly integrating with our app design and context.”
Implementing a consent management platform is vital for protecting website and app visitors’ information and building their trust. InMobi CMP ensures data transparency and allows users to manage their data permissions, reinforcing a commitment to a transparent data relationship. Designed to provide a seamless and non-intrusive consent process, CMPs help prioritise user privacy and offer clear options for data consent, creating a positive experience that enhances user satisfaction and trust.
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
